EMG
AEGR

Ellington Management Group’s Aegerion Pharmaceuticals AEGR Stock Holding History

Ellington Management Group’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-57,141
Closed -$577K – 845
2015
Q4 		$577K Buy
+57,141
New +$688K 0.2% 87
2014
Q1 		– Sell
-3,100
Closed -$220K – 867
2013
Q4 		$220K Sell
3,100
-2,200
-42% -$168K 0.08% 418
2013
Q3 		$454K Sell
5,300
-4,500
-46% -$381K 0.09% 357
2013
Q2 		$621K Buy
+9,800
New +$520K 0.12% 231

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ellington Management Group's AEGR Position: Q1 2016 in Review

Ellington Management Group sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2016, closing a stake of 57,141 shares — an estimated $577K sold.

Ellington Management Group first reported a position in AEGR in Q2 2013 and held it in 4 quarters. The position peaked at $621K in Q2 2013. 101 funds tracked by Wall St. Rank hold AEGR as of Q1 2016.

  • Ellington Management Group reported no remaining Aegerion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Ellington Management Group sold 57,141 Aegerion Pharmaceuticals shares in Q1 2016, an estimated $577K.
  • Ellington Management Group first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Ellington Management Group's Aegerion Pharmaceuticals position peaked at $621K in Q2 2013.
  • 101 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2016.

Based on Ellington Management Group's 13F filing for Q1 2016, filed 16 May 2016.